



## IMMATICS PRESS RELEASE

### US Patent Office Grants the 100<sup>th</sup> Patent to Immatics Underpinning the Company's Leading Role in the Field of Innovative Immunotherapies

**Munich, Germany, January 3<sup>rd</sup>, 2019** – Immatics, a leading company in the field of cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued the 100<sup>th</sup> patent to Immatics.

This is a significant achievement for the Company and demonstrates the breadth of Immatics' innovation power and the quality of its science. Immatics' strong patent portfolio enables the Company to develop its pipeline of cancer immunotherapies, to protect Immatics' innovations and to safeguard the Company's technology investments.

Immatics' 100<sup>th</sup> patent (US Patent No 10,143,731) is directed against a peptide target discovered using the Company's XPRESIDENT<sup>®</sup> technology. The peptides identified by XPRESIDENT<sup>®</sup> are presented by human leucocyte antigen (HLA) receptors on the surface of cells and are central to developing a range of novel powerful immunotherapies.

“Since its inception, Immatics has put a key focus on the development of its Intellectual Property estate, in order to protect our technology innovations in this highly competitive field”, said Dr. Rainer Kramer, CBO of Immatics. “Being awarded the 100<sup>th</sup> issued US patent in the Life Science industry is fantastic, proving that our inventions move Immatics further to the forefront of the highly competitive field of Immunotherapy development.”

Immatics' patenting strategy ensures broad protection of the Company's products, technologies and methods while still meeting the patentability requirements in the USA in a fast-paced environment.



## **About Immatics**

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The Company's transformative product candidates are – best in class – Adoptive Cell Therapies and TCER® Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology. XPRESIDENT® is the most sensitive, unbiased and high-throughput technology capable of identifying targets in virtually any type of cancer and any HLA type. Together with Immatics' powerful TCR discovery technology XCEPTOR®, these two platforms allow a full range of cancer therapies to be developed.

Immatics' pipeline includes T-cell therapy programs based on the proprietary ACTolog®, ACTengine® and ACTallo® approaches, which are developed in collaboration through Immatics US with University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT), and several bispecific TCR and antibody molecules.

Operating from Tuebingen, Munich and Houston, the Company has recognized that novel, better and safer targets are the key to developing future cancer immunotherapies and it is Immatics' mission to deliver the power of T cells to cancer patients.

For regular updates about Immatics, visit [www.immatics.com](http://www.immatics.com).

## **Media contact:**

Dr. Nikola Wiegeler

Phone : +49 7071 5397 110

[media@immatics.com](mailto:media@immatics.com)

You have received this information due to your interest in Immatics (Immatics Biotechnologies GmbH / Immatics US, Inc.). We hope you find this information useful to update you on the developments at Immatics.

Immatics would like to continue to send you information by Email. If you would prefer not to receive these Emails, please [unsubscribe here](#).